MALVERN, Pa., Might 10, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Firm) (NASDAQ: OCGN), a biotechnology firm targeted on discovering, growing, and commercializing novel gene and cell therapies and vaccines, right now introduced that its Board of Administrators declared a dividend of 1 one-thousandth of a share of newly designated Collection C Most popular Inventory, par worth $0.01 per share, for every excellent share of the Firm’s frequent inventory held of report as of 5:00 p.m. Jap Time on Might 20, 2024. The shares of Collection C Most popular Inventory will likely be distributed to such recipients at 5:00 p.m. Jap Time on Might 22, 2024. The excellent shares of Collection C Most popular Inventory will vote along with the excellent shares of the Firm’s frequent inventory, as a single class, completely with respect to sure stockholder proposals, and won’t be entitled to vote on some other matter, besides to the extent required beneath the DGCL. Topic to sure limitations, every excellent share of Collection C Most popular Inventory could have 1,000,000 votes per share (or 1,000 votes per one one-thousandth of a share of Collection C Most popular Inventory).
All shares of Collection C Most popular Inventory that aren’t current in individual or by proxy on the assembly of shareholders held to vote on the sure proposals as of instantly previous to the opening of the polls at such assembly will routinely be redeemed by the Firm and shall don’t have any voting energy. Any excellent shares of Collection C Most popular Inventory that haven’t been so redeemed will likely be redeemed if such redemption is ordered by the Firm’s Board of Administrators or routinely upon the approval by the Firm’s shareholders of sure proposals at such assembly.
The Collection C Most popular Inventory will likely be uncertificated, and no shares of Collection C Most popular Inventory will likely be transferable by any holder thereof besides in reference to a switch by such holder of any shares of the Firm’s frequent inventory held by such holder. In that case, quite a lot of one one-thousandths of a share of Collection C Most popular Inventory equal to the variety of shares of the Firm’s frequent inventory to be transferred by such holder can be transferred to the transferee of such shares of frequent inventory.
Additional particulars concerning the Collection C Most popular Inventory will likely be contained in a report on Kind 8-Ok to be filed by the Firm with the Securities and Alternate Fee.
About Ocugen, Inc.
Ocugen, Inc. is a biotechnology firm targeted on discovering, growing, and commercializing novel gene and cell therapies and vaccines that enhance well being and provide hope for sufferers throughout the globe. We’re making an impression on affected person’s lives by brave innovation—forging new scientific paths that harness our distinctive mental and human capital. Our breakthrough modifier gene remedy platform has the potential to deal with a number of retinal ailments with a single product, and we’re advancing analysis in infectious ailments to help public well being and orthopedic ailments to deal with unmet medical wants. Uncover extra at www.ocugen.com and observe us on X and LinkedIn.
Ahead Trying Statements
This press launch incorporates forward-looking statements inside the which means of The Non-public Securities Litigation Reform Act of 1995, together with, however not restricted to, statements concerning qualitative assessments of obtainable knowledge, potential advantages, expectations for ongoing medical trials, anticipated regulatory filings and anticipated growth timelines, that are topic to dangers and uncertainties. We might, in some instances, use phrases similar to “predicts,” “believes,” “potential,” “proposed,” “proceed,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “might,” “may,” “may,” “will,” “ought to,” or different phrases that convey uncertainty of future occasions or outcomes to determine these forward-looking statements. Such statements are topic to quite a few vital elements, dangers, and uncertainties that will trigger precise occasions or outcomes to vary materially from our present expectations, together with, however not restricted to, the dangers that preliminary, interim and top-line medical trial outcomes will not be indicative of, and should differ from, ultimate medical knowledge; that unfavorable new medical trial knowledge might emerge in ongoing medical trials or by additional analyses of present medical trial knowledge; that earlier non-clinical and medical knowledge and testing of will not be predictive of the outcomes or success of later medical trials; and that that medical trial knowledge are topic to differing interpretations and assessments, together with by regulatory authorities. These and different dangers and uncertainties are extra totally described in our periodic filings with the Securities and Alternate Fee (SEC), together with the danger elements described within the part entitled “Danger Components” within the quarterly and annual reviews that we file with the SEC. Any forward-looking statements that we make on this press launch communicate solely as of the date of this press launch. Besides as required by legislation, we assume no obligation to replace forward-looking statements contained on this press launch whether or not on account of new data, future occasions, or in any other case, after the date of this press launch.
Contact:
Tiffany Hamilton
Head of Communications
Tiffany.Hamilton@ocugen.com
